...
首页> 外文期刊>Journal of Cranio-Maxillofacial Surgery >Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docebaxel - three year results of a pilot study.
【24h】

Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docebaxel - three year results of a pilot study.

机译:口腔和口咽癌的联合治疗方法,包括新辅助动脉内顺铂和根治性手术,然后同时进行放射治疗和每周docebaxel化疗-一项初步研究的三年结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Background: A new four-modality treatment of primary oral and oropharyngeal squamous cell carcinomas was evaluated with regard to feasibility, tolerance, and survival. Patients and methods: Seventy three operable patients (100%) with histologically proven untreated stage I to stage IV disease received at least one cycle of neoadjuvant intraarterial chemotherapy with 150 mg/m(2) cisplatin neutralized with sodium thiosulphate, followed by radical operation for the tumour with a simultaneous selective neck dissection (clinically negative neck), or modified radical neck dissection (nodal involvement), followed by adjuvant chemoradiation over 5 weeks (51.9 Gy, systemic docetaxel 25 mg/m(2), once every week). Results: Ninety-six per cent of patients were operated on, 68% had postoperative radiation, 57% concomitant chemotherapy; 44% fulfilled the complete protocol. There have been 11 local or regional recurrences to date, three of which were treated by salvage surgery. Eighteen patients died, in nine of them death was tumour-related. Seventy five per cent lived after a median observation time of 33 months. Cumulative survival was 74% calculated for 4 years. Conclusion: The presented multimodality regimen proved feasible and showed better survival for the whole population and for all tumour stages when compared with the treatment-dependent prognosis index of the DOSAK (German-Austrian-Swiss Cooperative Group on tumours of the maxillofacial region).
机译:背景:对原发性口腔和口咽鳞状细胞癌的一种新的四模式治疗方法进行了可行性,耐受性和存活率的评估。患者和方法:经组织学证实未经治疗的I至IV期疾病的73例可手术患者(100%)接受了至少一个周期的新辅助动脉内化疗,用硫代硫酸钠中和150 mg / m(2)顺铂,然后进行同时进行选择性颈淋巴清扫术(临床阴性颈)或改良根治性颈淋巴结清扫术(淋巴结受累),然后在5周内进行辅助化学放疗(51.9 Gy,全身性多西他赛25 mg / m(2),每周一次)。结果:96%的患者接受了手术,68%的患者接受了放射治疗,57%的患者接受了化疗。 44%的人完成了完整的协议。迄今为止,已有11例局部或区域复发,其中3例通过抢救手术治疗。 18例患者死亡,其中9例死亡与肿瘤有关。在平均观察时间为33个月之后,有75%的人活了下来。累积生存率为74%,计算4年。结论:与DOSAK(上颌面部肿瘤的德国-奥地利-瑞士合作小组)的治疗依赖性预后指标相比,所提出的多模式方案被证明是可行的,并且在整个人群和所有肿瘤阶段均显示出更好的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号